TITLE

Geographic location of antiretroviral clinical trials in HIV infected pediatric patients

AUTHOR(S)
Suda, Katie J.; Greene, Jodie; Shelton, Chasity M.
PUB. DATE
December 2013
SOURCE
International Journal of Clinical Pharmacy;Dec2013, Vol. 35 Issue 6, p1203
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Some medicines regulatory authorities are encouraging research in pediatrics. However, children are a vulnerable population, and previous studies have suggested that research is increasingly being conducted outside of developed countries. Objective The purpose of this study is to determine the location of trials in the pediatric population with human immunodeficiency virus (HIV). Setting Not applicable. Methods Clinical trials registered in the largest international clinical trials registry (clinicaltrials.gov) evaluating antiretrovirals in pediatric HIV infected patients were included. Data were collected on the location, funding, study purpose, design, initiation date, age of subjects, and medication classes tested. Main outcome measures We assessed frequencies of characteristics of pediatric HIV trials registered in the clinicaltrials.gov database. Results Overall, 288 studies were included in the analysis. Most trials were conducted in ages 12–17 years (83 %), followed by studies in those <6 years (25 %) and 6–11 years (21 %). The location of most trials included at least one site in developed countries (83 %). The number of trials completed exclusively in developing countries increased from 1989 to 2011. Conclusions The majority of pediatric antiretroviral trials registered in clinicaltrials.gov were conducted in adolescent subjects in developed countries. The number of pediatric HIV studies in developing countries increased while studies conducted in developed countries decreased similar to trends of HIV.
ACCESSION #
92719582

 

Related Articles

  • The Use of Pill Counts as a Facilitator of Adherence with Antiretroviral Therapy in Resource Limited Settings. Achieng, Loice; Musangi, Helen; Billingsley, Katherine; Onguit, Sharon; Ombegoh, Edwin; Bryant, LeeAnn; Mwiindi, Jonathan; Smith, Nathaniel; Keiser, Philip // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background:Pill counts are often used to measure adherence to ART, but there is little data on how they affect adherence. We previously showed a bivariate relationship between clinicians counting pills and adherence in patients receiving HIV care in Kenya. We present a secondary analysis of the...

  • Impact of Prior HAART Use on Clinical Outcomes in a Large Kenyan HIV Treatment Program. Chung, Michael H.; Drake, Alison L.; Richardson, Barbra A.; Reddy, Ashok; Thiga, Joan; Sakr, Samah R.; Kiarie, James N.; Yowakim, Paul; John-Stewart, Grace C. // Current HIV Research;Jul2009, Vol. 7 Issue 4, p441 

    Background: HIV treatment programs in Africa typically approach all enrolling patients uniformly. Growing numbers of patients are antiretroviral experienced. Defining patients on the basis of antiretroviral experience may inform enrollment practices, particularly if medical outcomes differ....

  • Determinants of Antiretroviral Therapy Initiation and Treatment Outcomes for People Living With HIV in Vietnam. Tran, Dam Anh; Shakeshaft, Anthony; Ngo, Anh Duc; Mallitt, Kylie-Ann; Wilson, David; Doran, Christopher; Lei Zhang // HIV Clinical Trials;Jan/Feb2013, Vol. 14 Issue 1, p21 

    Objectives: This study explores patient characteristics that are significantly associated with very late combination antiretroviral therapy (cART) initiation (CD4 count ≤100 cells/mm³) and examines the association between patient characteristics and treatment outcomes, CD4 recovery, and...

  • Is Starting ART earlier in patients with ATT beneficial? Malik, Amyn A. // Journal of Pakistan Medical Students;Apr-Jun2012, Vol. 2 Issue 2, p46 

    The article presents information on medical studies on antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-positive people with tuberculosis (TB) published in medical journals in 2011. A study by X. F. Blanc and colleagues compared the outcomes of earlier and later start of ART in...

  • Earlier ART may improve HIV clinical outcomes. Ellis, Kirsten H. // Infectious Disease News;May2008, Vol. 21 Issue 5, p34 

    The article discusses research being done on the early administration of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients. It references a study by S. Emery and colleagues, published in the 2008 issue of "The Journal of Infectious Diseases." Study researchers...

  • Outcome in Patients with Non-Hodgkin Lymphoma and With or Without Human Immunodeficiency Virus Infection. Spina, Michele; Carbone, Antonino; Vaccher, Emanuela; Gloghini, Annunziata; Talamini, Renato; Cinelli, Roberta; Martellotta, Ferdinando; Tirelli, Umberto // Clinical Infectious Diseases;1/1/2004, Vol. 38 Issue 1, p142 

    No abstract available.

  • Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients. Espíndola, Milena S.; Lima, Leonardo J. G.; Soares, Luana S.; Cacemiro, Maira C.; Zambuzi, Fabiana A.; de Souza Gomes, Matheus; Amaral, Laurence R.; Bollela, Valdes R.; Martins-Filho, Olindo A.; Frantz, Fabiani G. // PLoS ONE;12/18/2015, Vol. 10 Issue 12, p1 

    Background: Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological...

  • Factors Associated with Late Antiretroviral Therapy Initiation among Adults in Mozambique. Lahuerta, Maria; Lima, Josue; Nuwagaba-Biribonwoha, Harriet; Okamura, Mie; Alvim, Maria Fernanda; Fernandes, Rufino; Assan, Americo; Hoos, David; Elul, Batya; El-Sadr, Wafaa M.; Nash, Denis // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Background: Despite recent changes to expand the ART eligibility criteria in sub-Saharan Africa, many patients still initiate ART in the advanced stages of HIV infection, which contributes to increased early mortality rates, poor patient outcomes, and onward transmission. Methods: To evaluate...

  • News from ISPOR.  // PharmacoEconomics & Outcomes News;6/30/2007, Issue 531, p6 

    The article focuses on various studies presented at the 12th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Arlington, Virginia in May 2007. Swedish researchers reported that varenicline is more cost effective than bupropion for smoking...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics